Investors & Partners · SOULSKIPPER Limited

Turning development
into company value.

SOULSKIPPER Limited brings together two distinct product lines: FABS AI for wellness and research, and NOMAD AI for mobile applications and remote support. Their development stages, goals and requirements are considered separately.

A starting point for discussion

FABS AI is at an early stage. We seek partners to help build a research prototype, assess the technology and develop the business. The proposed model combines equipment, software and supporting services.

Capital requirements and investment terms are not yet fixed. Funding depends on priorities, including technical development and the costs of at least two potential patent applications for FABS AI. An early medical-device approval pathway requires additional testing, documentation and funding. Alternatively, investors could initially support a premium wellness offering without medical approval as the first market goal. Next steps should follow a transparent budget and milestone plan.

FABS AI · Starting point

A platform in early development

FABS AI is at the concept and early development stage. The vision combines an open couch, sound, perceptible vibration, electromagnetic stimulation and body-signal recording, focusing on individual responses.

The system investigates the combined use of spatially controllable electromagnetic and acoustic frequency fields: their interaction and targeted spatial distribution around the couch.

Next steps aim to turn the concept into a technically testable research platform. Product images are designs, not claims of completed technical or medical validation.

FABS AI · Business outlook

Equipment, software and supporting services

The proposed model includes FABS AI systems, additional software functions, training, maintenance and support for professional users. Licensing and strategic cooperation are also options.

These are planned business activities, not claims of existing revenue, signed customer contracts or achieved market readiness.

FABS AI · Scientific background

Understanding research.
Investigating effects systematically.

Research into electromagnetic stimulation, sound and mechanical vibration offers useful starting points, but no universal healing frequencies. Frequency, intensity, timing, duration and tissue matter. FABS AI draws on this work to develop its own investigations.

What cell studies show

A systematic review of 92 publications on pulsed electromagnetic fields (PEMF) describes measurable responses in cell cultures. Responses depend on cell type and application parameters. Such laboratory findings inform research questions; they do not establish therapeutic effects in humans.

Source: review of PEMF in cell cultures, 2021 ↗

Pain research: opportunities and open questions

Clinical PEMF evidence varies by application. A knee osteoarthritis meta-analysis of nine randomised studies with 457 participants reports time-dependent improvements in some symptoms, but not consistently clear findings. Different protocols and high risk of bias limit firm conclusions. Statistical improvements may not translate into noticeable everyday benefits.

Source: PEMF meta-analysis for knee osteoarthritis, 2026 ↗

Different forms of magnetic stimulation

Repetitive transcranial magnetic stimulation (rTMS) targets specific brain regions with magnetic pulses. It is a distinct medical procedure with defined safety requirements. Findings and settings cannot simply be transferred to a whole-body couch. FABS AI is not equated with a clinically validated rTMS system.

Source: FDA guidance on rTMS systems ↗

Distinguishing sound and vibration

A systematic review of whole-body vibration for non-specific back pain reports improvements in several studies but highlights varied applications and the need for standardised research. Results do not automatically apply to couch-based vibroacoustics. Sound, music, binaural beats and mechanical vibration are different approaches. Binaural beats arise perceptually from two tones presented separately to the ears; they are not a physically emitted low-frequency tone.

Source: whole-body vibration review for back pain, 2023 ↗

What this means for FABS AI

We investigate whether objective body signals can improve understanding of individual responses and support more targeted adaptation within predefined safety limits. Planned AI will evaluate several factors together, supported by a systematically built parameter and measurement database, rather than simply choosing one frequency.

This is a research goal, not an established advantage. Safety and potential therapeutic benefit require studies of the complete system. Cell-culture findings and other devices' results cannot replace them. Implementation details are discussed confidentially.

FABS AI · Tesla and Lakhovsky · Possible future research

Historical foundations.
New research questions.

Nikola Tesla's resonant high-frequency circuits form part of electrical engineering history. Energy moves between a capacitor and a coil, producing rapid electrical oscillations. This background offers possible further research questions for FABS AI.

Developing the proposed platform first

The initial focus is electromagnetic fields, sound and felt vibration. Body-signal recording and AI analysis are intended to investigate individual responses and adapt applications within predefined programme limits. These components are the proposed focus of the first research prototype.

High frequency as a separate possibility

Resonant high-frequency fields could become an additional research direction. They are not a confirmed part of the first prototype. A later stage would separately assess feasibility, safety and possible medical benefit.

Georges Lakhovsky: considering multiple frequencies

Georges Lakhovsky, an inventor working in France, offers another historical reference. His multiwave oscillator uses nested open rings of different sizes to produce several electromagnetic wavelengths. The technical idea is to excite different resonances together: conductive structures respond differently according to their construction.

FR732276A and US1962565A, granted in 1934, document this approach. US2351055A (1944) describes a tube-based construction for generating or conducting several wavelengths in a more compact device. The later publication EP2862596A1 also refers to Lakhovsky's multiwave antenna.

A possible FABS AI research question is how individual-frequency responses differ from responses to defined combinations. This connects historical technology with planned individual body-signal analysis. It is our interpretation for possible future research, not a confirmed FABS AI function or effect.

Historical inspiration, independent development

FABS AI is conceived as an independent platform. Copper coils generate time-varying electromagnetic fields, speakers produce sound and transducers deliver mechanical vibration through the couch. Their programmable coordination and assessment alongside body signals may offer development value through individual response analysis and controlled adaptation under human supervision.

Electrical and acoustic frequencies differ: the same numerical frequency does not make an electromagnetic field equivalent to a sound wave. FABS AI is therefore not the historical high-frequency multiwave oscillator. Tesla and Lakhovsky provide inspiration; recreating their devices is not the development goal.

Four functional areas, one programmable platform

The proposed FABS AI couch combines several stimulation methods. Multimodal here means bringing electromagnetic fields, sound and mechanical vibration into one research platform.

Electromagnetic stimulation: Copper coils around the head, sides and feet generate time-varying electromagnetic fields.
Sound and body vibration: Speakers and suitable transducers provide sound and perceptible mechanical vibration.
Central control: A planned controller coordinates settings and timing within defined limits.
Programme management: Software links programme selection, the session and body-signal recording. Planned AI supports analysis and supervised adaptation.

For investors, the opportunity concerns an integrated platform of hardware, control and analysis. Based on thorough patent searches already conducted, the founder considers the likelihood of obtaining patents for two distinct FABS AI developments very high. A patent attorney has not yet been engaged; specialist review and preparation of applications are planned for the next investor-funded development round.

Lakhovsky's historical biological resonance and therapeutic ideas are treated as hypotheses. Patents do not replace clinical evidence. Adopting his device construction is not decided; extensions would undergo separate safety, measurement and third-party rights assessment.

Sources: Multiwave oscillator, FR732276A ↗ · Multiple wavelengths, US1962565A (1934) ↗ · Tube construction, US2351055A (1944) ↗ · Later reference, EP2862596A1 ↗

Assessing existing patents carefully

Historical patents describe electrotherapeutic devices with Tesla coils; newer publications cover Tesla coils for cell stimulation and frequency-controlled therapy devices. They are relevant prior-art references, not scientific evidence of effectiveness.

Before developing a high-frequency extension, detailed patent review is planned, covering claims, current protection and third-party rights. Patentability and freedom to implement without infringing others' rights are separate questions. These documents are research starting points, not a substitute for review.

Patent references: Tesla: high-frequency currents, US568180A (1896) ↗ · Historical electrotherapeutic device, US1012326A ↗ · Cell therapy or stimulation device, DE112020006034B4 ↗ · Frequency-controlled therapy device, WO2015007840A1 ↗

Where we stand.
The next step.

Existing foundation

FABS AI product concept, visualisations, development direction and proposed business model. NOMAD has a separate development history documented by historical photographs.

Planned evidence

Building and testing a research prototype, technical validation and initial scientific studies. Available materials do not establish completion of these steps.

To be agreed in discussion

Cost model, funding, schedule, measurable milestones and possible investment or cooperation terms.

What funding is intended to enable

FABS AI planning involves successive stages, with scope, sequence and funding agreed against specific development goals.

Develop technology and softwareIntegrate components, test their interaction and advance the software.
Build a research prototypeBring the concept together in a testable, demonstrable platform.
Assess function and research approachInvestigate technical reliability and prepare scientifically assessable trials.
Prepare further implementationUse findings to plan quality assurance, eventual pilot production and market access.

No specific funding sum is fixed. It will be based on costs, priorities and agreed milestones.

Collaboration

Capital, expertise and development partners

FABS AI seeks investors, strategic and development partners, and potential licensees. Beyond funding, this means collaboration from concept to validated technology platform.

NOMAD AI focuses on its own mobile applications. Discussions are separate; FABS funding plans do not automatically apply to NOMAD AI.

Confidential discussion

Understand the outlook. Discuss the details.

Protecting technology, brand, design and know-how is part of planned company development. Rights are sought; granted patents or completed registrations are not claimed here.

Public disclosure before filing can jeopardise novelty in Europe, which lacks a general novelty grace period unlike the USA under certain conditions. We therefore reserve detailed FABS AI and NOMAD AI information for serious investors and prospective partners in personal discussions under agreed confidentiality. Protection strategy and financing terms are also confidential. Medical applications remain a long-term perspective.

FABS AI · Intellectual property outlook

Two potential patent applications

Based on thorough patent searches already conducted, the founder considers the likelihood of patents for two distinct FABS AI developments very high.

No patent attorney has yet been engaged. Specialist review and preparation of both applications are planned for the next investor-funded round. This assessment describes expected IP potential; patents have not yet been granted. Invention details and potential claims remain confidential.

Commercial strategy

Growth, licensing or eventual acquisition

Licensing future granted patents could generate fees without selling SOULSKIPPER. Income would depend on granted rights, demand and licensing agreements.

Alongside developing the company and possible licensing, eventual acquisition by a larger business is considered an option, potentially allowing investors to participate in created company value.

Potential sectoral connections include Siemens Healthineers in medical technology, diagnostics and digital health; Hitachi High-Tech in medical analytics and healthcare technology; and GE HealthCare in medical technology, monitoring and digital care. GE HealthCare is now independent of General Electric. These examples are the founder's strategic considerations, not evidence of interest, partnerships or acquisition talks. Neither acquisition nor profit is guaranteed.

NOMAD AI · Audience and positioning

Field technology for a wider audience

In the founder's experience, comparable government and military solutions can be complex, specialist-focused and available through restricted procurement rather than readily accessible to private users. NOMAD AI also targets small municipalities and individuals, aiming to make mobile communication and support accessible without technical expertise.

Automatic one-button operation and self-explanatory guidance are development goals, especially under stress. This is not yet a proven competitive advantage; systematic market analysis and practical usability tests remain next steps.

NOMAD AI · Planned series production

International production. Personal quality oversight.

The planned production chain places the case and in-house battery in Germany, the computer unit in Taiwan, and other components and AR glasses in Shenzhen, China.

LJUBOMIR FILIPOVIC will personally oversee production and final quality inspection in China with his Chinese business partners, coordinating quality across the chain from component selection to final checks.

Security-relevant components can additionally be monitored directly during production. This supports traceable origin and component integrity. For later sensitive applications, privacy and technical security also require appropriate testing, documented controls and system-level safeguards; personal oversight is one important element.

NOMAD AI · Case development experience

Tested in
demanding environments.

Current development builds on earlier practical trials. The founder reports successful tests with Airbus in Hamburg, Pfizer in Freiburg and Germany's Federal Agency for Technical Relief (THW). These examples describe historical development experience.

Airbus · Hamburg

A trial concerned quality control in door manufacturing. The founder reports successful testing.

Watch the Airbus video on YouTube (opens a new tab)

Watch on YouTube

Pfizer · Freiburg

The case was tested for AI-assisted final inspection after cleaning pharmaceutical cleanrooms. The founder reports a successful trial.

Pfizer's Freiburg site ↗

Federal Agency for Technical Relief · Freiburg

The founder reports another successful trial with THW in Germany involving its Freiburg office.

Earlier development and testing with THW Freiburg.

Pfizer trial: demanding environmental conditions

The founder describes high temperature, very high humidity and airborne chemicals as particular challenges for the tested case configuration.

Project accounts describe a special battery, selected displays and a custom construction using a special stainless-steel alloy. The founder reports that the case successfully withstood the trial conditions.

This concerns that configuration and those conditions, not general resistance to all chemicals or validation of other equipment and limits.

Medical research · Development experience

AI-assisted wound detection and care

The latest major medical research project with substantial involvement by LJUBOMIR FILIPOVIC investigated foundations of AI-assisted wound detection and care. He reports involvement of one of Germany's largest care providers and Charité university hospital.

As Chief Developer, he was responsible for hardware and AI software implementation, working with scientists on tools to support care assistants and trained nursing staff caring for patients at home.

Partially obscured project image of AI-assisted wound detection — Project image of AI-assisted wound detection, partially obscured for ethical reasons. The developer states that the underlying originals are of very high quality.

The aim was to capture images for diagnostic assessment, consult doctors through telemedicine and use AI to generate automated care documentation. Clinical judgement remained central.

His work included optical systems and specialised high-resolution cameras, connecting mobile hardware, image processing and remote medical support within the case's development history.

Context: these trial accounts come from the founder. Dated reports, measurement records and written confirmations were not provided for this preview. Named organisations are not presented as current SOULSKIPPER partners, customers or supporters. The experiences concern the case, not evidence of FABS AI effectiveness or validation.

Start a conversation with SOULSKIPPER

LJUBOMIR FILIPOVIC · Founder, Chief Developer and Chief Executive Officer (CEO) · SOULSKIPPER Limited

Discuss investment or partnership

Sources on patent rules and company sectors

European Patent Office: novelty and grace periods · US Patent Office: disclosure and grace periods · Siemens Healthineers: business areas · Hitachi High-Tech: healthcare · GE HealthCare: business areas · GE HealthCare: independent company

Turning developmentinto company value.